Back to Trades
Sell4
MADRIGAL PHARMACEUTICALS, INC.
MDGL
Total Value
$50.3M
Net $47.8M sold
Sales
$47.8M
17 transactions
Company Information
- Company Name
- MADRIGAL PHARMACEUTICALS, INC.
- Ticker Symbol
- MDGL
- CIK
- 0001157601
Insider Information
- Name
- FRIEDMAN PAUL A
- Role
- Director
- Location
- WEST CONSHOHOCKEN, PA
Director
Filing Details
- Filing Date
- Aug 13, 2025
- Transaction Date
- Aug 13, 2025
- Accession Number
- 0001236927-25-000007
- Form Type
- 4
- Net Trading Amount
- -$47.8M
Non-Derivative Transactions
| Date | Security | Shares | Price | Type | Value |
|---|---|---|---|---|---|
| Aug 13, 2025 | Common Stock | 129,172 | $9.45 | Exercise | $1.2M |
| Aug 13, 2025 | Common Stock | 1,600 | $358.23 | Sale | $573.2K |
| Aug 13, 2025 | Common Stock | 455 | $359.31 | Sale | $163.5K |
| Aug 13, 2025 | Common Stock | 3,153 | $360.27 | Sale | $1.1M |
| Aug 13, 2025 | Common Stock | 1,754 | $361.13 | Sale | $633.4K |
| Aug 13, 2025 | Common Stock | 1,439 | $362.29 | Sale | $521.3K |
| Aug 13, 2025 | Common Stock | 2,591 | $363.08 | Sale | $940.7K |
| Aug 13, 2025 | Common Stock | 3,529 | $364.02 | Sale | $1.3M |
| Aug 13, 2025 | Common Stock | 1,716 | $365.19 | Sale | $626.7K |
| Aug 13, 2025 | Common Stock | 3,152 | $366.22 | Sale | $1.2M |
| Aug 13, 2025 | Common Stock | 7,119 | $367.31 | Sale | $2.6M |
| Aug 13, 2025 | Common Stock | 6,788 | $368.34 | Sale | $2.5M |
| Aug 13, 2025 | Common Stock | 7,992 | $369.44 | Sale | $3.0M |
| Aug 13, 2025 | Common Stock | 7,877 | $370.44 | Sale | $2.9M |
| Aug 13, 2025 | Common Stock | 22,710 | $371.53 | Sale | $8.4M |
| Aug 13, 2025 | Common Stock | 28,976 | $372.39 | Sale | $10.8M |
| Aug 13, 2025 | Common Stock | 24,166 | $373.35 | Sale | $9.0M |
| Aug 13, 2025 | Common Stock | 4,155 | $374.38 | Sale | $1.6M |
Derivative Transactions
| Date | Security | Shares | Exercise Price | Type | Value |
|---|---|---|---|---|---|
| Aug 13, 2025 | Derivative | 129,172 | $9.45 | Exercise | $1.2M |
Footnotes
- (F1)These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025.
- (F2)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $357.70 to $358.67, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- (F3)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $358.71 to $359.68, inclusive.
- (F4)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $359.71 to $360.67, inclusive.
- (F5)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $360.72 to $361.62, inclusive.
- (F6)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $361.73 to $362.70, inclusive.
- (F7)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $362.74 to $363.73, inclusive.
- (F8)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $363.78 to $364.77, inclusive.
- (F9)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $364.79 to $365.75, inclusive.
- (F10)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $365.89 to $366.88, inclusive.
- (F11)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $366.90 to $367.88, inclusive.
- (F12)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $367.90 to $368.89, inclusive.
- (F13)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $368.90 to $369.88, inclusive.
- (F14)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $369.90 to $370.88, inclusive.
- (F15)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $370.92 to $371.91, inclusive.
- (F16)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $371.92 to $372.91, inclusive.
- (F17)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $372.92 to $373.90, inclusive.
- (F18)The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $373.94 to $374.60, inclusive.
- (F19)The Reporting Person and his spouse are each managing members of SQN, LLC. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of the beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
- (F20)The shares underlying this stock option are fully vested and exercisable.